# The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

> **NCT03951623** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 45 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** HMPL-523
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03951623
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-12
- **Primary completion:** 2021-10-30
- **Final completion:** 2022-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03951623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03951623, "The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03951623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*